Stockscreener 앱 받기
95.93
1.73%
1.63
Incyte Corp 주식(INCY)의 최신 뉴스
Adagene reveals Incyte deal, data update and public offering - The Pharma Letter
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC) - Yahoo Finance
Citizens reiterates Incyte stock rating on pipeline progress - Investing.com
J. Safra Sarasin Holding AG Decreases Stake in Incyte Corporation $INCY - MarketBeat
Barclays Maintains Overweight on Incyte (INCY) Mar 2026 - Meyka
Incyte Corp. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Incyte Corp (INCY) Price Target Hiked at UBS on Sales and Earnings Growth Prospects - MSN
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corporation (INCY) Announces Board Member Resignation - gurufocus.com
Incyte board member Susanne Schaffert to step down in April By Investing.com - Investing.com India
Incyte board member Susanne Schaffert to step down in April - Investing.com
Incyte's Susanne Schaffert to Resign from Board Effective April 15, 2026 - TradingView
INCY: HC Wainwright & Co. Reiterates 'Buy' Rating and $135 Price Target | INCY Stock News - GuruFocus
Incyte Shares Positive 54-Week Results From Advanced Skin Condition Trial - Bitget
Incyte Reports Strong 54-Week Data From Late-Stage Skin Disorder Study - Yahoo Finance
William Blair reiterates Market Perform on Incyte stock after HS data - Investing.com Canada
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
Stifel reiterates Incyte stock rating on hidradenitis drug data By Investing.com - Investing.com India
Stifel reiterates Incyte stock rating on hidradenitis drug data - Investing.com
A Look Back at Biotechnology Stocks’ Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack - Yahoo Finance
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting - Yahoo Finance
(INCY.O) | Stock Price & Latest News - Reuters
Incyte Corporation $INCY Shares Purchased by SG Americas Securities LLC - MarketBeat
Incyte Corp. stock outperforms competitors despite losses on the day - MarketWatch
Vanguard disaggregates holdings; reports 0% in Incyte (INCY) - Stock Titan
Incyte Corporation (INCY) Announces Executive Leadership Title C - GuruFocus
Incyte Announces Key Executive Leadership Changes and Integration of U.S. Commercial Teams for Long-Term Growth - minichart.com.sg
INCYTE (NASDAQ: INCY) EVP sees 537 shares withheld to cover RSU taxes - Stock Titan
Pablo J. Cagnoni named President at Incyte; William J. Meury remains CEO - TradingView
Incyte (NASDAQ: INCY) appoints new President and consolidates U.S. commercial - Stock Titan
UBS Lowers Price Target for Incyte (INCY) While Maintaining Neut - GuruFocus
Barclays Maintains Overweight on INCY Incyte Corporation March 2026 - Meyka
Incyte Corp. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Incyte Appoints Three to Executive Leadership Positions - Contract Pharma
UBS lowers Incyte stock price target on revenue concerns to $94 - Investing.com Australia
UBS Group Lowers Incyte (NASDAQ:INCY) Price Target to $94.00 - marketbeat.com
KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data - Yahoo! Finance Canada
Incyte announces executive leadership changes, integrates U.S. teams - Investing.com
Incyte Announces Executive Leadership Appointments - Business Wire
H.C. Wainwright reiterates Incyte stock rating citing oral drug potential - Investing.com
HC Wainwright Reiterates Buy Rating for Incyte (INCY) | INCY Sto - GuruFocus
A Look At Incyte (INCY) Valuation After Mixed Short Term Returns And Strong One Year Performance - Yahoo Finance
Barclays reiterates Incyte stock rating after mixed trial results - Investing.com
Barclays reiterates Incyte stock rating after mixed trial results By Investing.com - Investing.com UK
Nordea Investment Management AB Acquires 291,293 Shares of Incyte Corporation $INCY - MarketBeat
Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm Research - Barchart.com
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace
Swiss Life Asset Management Ltd Increases Stake in Incyte Corporation $INCY - MarketBeat
New England Research & Management Inc. Acquires New Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corporation $INCY Shares Sold by JPMorgan Chase & Co. - marketbeat.com
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
INCY wins EC approval for label expansion of oncology drug Zynyz - MSN
Analysts differ in opinion on Jakafi drug maker Incyte (INCY) - MSN
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data a - The National Law Review
0.49%
1.47%
자본화:
|
볼륨(24시간):